Nuvectis Pharma (NVCT) EBITDA (2021 - 2026)

Nuvectis Pharma (NVCT) has 6 years of EBITDA data on file, last reported at -$6.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 12.43% year-over-year to -$6.3 million; the trailing twelve-month figure through Mar 2026 stood at -$28.3 million (down 34.48% YoY), and the FY2025 full-year result was -$27.6 million, down 38.93% from the prior year.
• EBITDA climbed to -$6.3 million in Q1 2026, from -$7.6 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$2.9 million in Q1 2022 to a low of -$7.8 million in Q3 2025.
• A 5-year average of -$5.6 million and a median of -$5.9 million in 2022 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 39.83% in 2022, while the deepest fall reached 199.25% in 2022.
• Tracing NVCT's EBITDA over 5 years: stood at -$6.8 million in 2022, then slipped by 1.3% to -$6.9 million in 2023, then increased by 6.07% to -$6.4 million in 2024, then retreated by 18.11% to -$7.6 million in 2025, then climbed by 17.82% to -$6.3 million in 2026.
• Business Quant data shows NVCT's EBITDA at -$6.3 million in Q1 2026, -$7.6 million in Q4 2025, and -$7.8 million in Q3 2025.